Biocon shares gain 5% on launch of Ogivri biosimilar in US
Updated : December 03, 2019 11:20 AM IST
Shares of Biocon rose 5 percent on Tuesday after the company launched Trastuzumab biosimilar Ogivri in the US market.
The company with its partner Mylan NV announced the US launch of Ogivri.
So far in 2019, Biocon has underperformed the market, falling 9 percent as compared to around 11 percent rise in the benchmark Nifty50.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more